Ivonescimab + Pembrolizumab for Lung Cancer

Recruiting at 453 trial locations

Overseen By Summit Clinical Trial Information

Age: 18+

Sex: Any

Trial Phase: Phase 3

Sponsor: Summit Therapeutics

Disqualifiers: Small cell lung cancer, Genomic alterations, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Pivotal Trial (Near Approval) This treatment is in the last trial phase before FDA approval

Prior Safety Data This treatment has passed at least one previous human trial

Compensation: Varies

Number of Visits: Unknown

Duration: up to 2 years

1600 Participants Needed

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial tests two treatment combinations for people with metastatic non-small cell lung cancer (NSCLC). One group receives ivonescimab (a PD-1/VEGF bi-specific antibody) with chemotherapy, while the other receives pembrolizumab with chemotherapy. The main goal is to determine which combination helps patients live longer and prevents cancer growth. People with Stage IV NSCLC who have not received prior treatment might be suitable for this study. As a Phase 3 trial, this study represents the final step before FDA approval, offering patients access to potentially groundbreaking treatments.

Will I have to stop taking my current medications?

The trial information does not specify if you need to stop taking your current medications. However, it mentions that participants should not have received any prior therapy for metastatic non-small cell lung cancer.

Is there any evidence suggesting that this trial's treatments are likely to be safe?

Research has shown that ivonescimab, when combined with chemotherapy, can be safely administered to patients with advanced non-small cell lung cancer. In earlier studies, patients tolerated it well, and it demonstrated promising tumor-fighting results without major safety concerns.

Pembrolizumab has extensive safety information available due to its approval for several conditions. It is usually well-tolerated, though some patients may experience immune-related side effects, such as skin rashes or mild inflammation. These side effects are generally manageable with standard treatments.

Both treatments in this trial have demonstrated safety for patients, making them promising options for those considering participation. ^{1 2 3 4 5}

Why are researchers excited about this trial's treatments?

Researchers are excited about these treatments for lung cancer because they offer unique approaches compared to standard options like chemotherapy and existing immunotherapies. Ivonescimab is an innovative treatment that combines the capabilities of a bispecific antibody targeting two different proteins, potentially enhancing the immune system's ability to attack cancer cells more effectively. Pembrolizumab, already a well-known immunotherapy, is being tested in combination with chemotherapy to assess its efficacy in new settings. These combinations aim to improve patient outcomes by harnessing the power of the immune system in different ways, potentially offering more effective and targeted treatment options.

What evidence suggests that this trial's treatments could be effective for lung cancer?

Research shows that ivonescimab, one of the treatments in this trial, has promising results for treating advanced non-small cell lung cancer when combined with chemotherapy. Ivonescimab targets two proteins, PD-1 and VEGF-A, which aid cancer growth. One study found that ivonescimab improved patient outcomes more effectively than pembrolizumab. Pembrolizumab, another treatment option in this trial, is well-known, with studies indicating that about 19-22% of patients live for five years when used with chemotherapy. Both treatments in this trial have shown effectiveness, offering hope for better survival rates in lung cancer patients. ^{1 3 4 5 6}

Who Is on the Research Team?

Indu Lal

Principal Investigator

Summit Therapeutics, Inc.

Are You a Good Fit for This Trial?

Adults with metastatic squamous non-small cell lung cancer (NSCLC) who have not had previous treatments for their advanced disease. Participants must have a certain level of PD-L1 expression, be in good physical condition (ECOG score 0 or 1), and expect to live at least three more months. They cannot join if they have small cell lung carcinoma, non-squamous NSCLC, major blood vessel involvement by the tumor, or known specific genetic alterations.

Inclusion Criteria

I haven't had any systemic treatment for my advanced lung cancer.

I am fully active or restricted in physically strenuous activity but can do light work.

You are expected to live for at least 3 more months.

Exclusion Criteria

My lung cancer is confirmed to be either small cell or non-squamous non-small cell.

My cancer has specific genetic changes in EGFR, ALK, or ROS1.

I have received treatment for my lung cancer after it spread.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive either ivonescimab or pembrolizumab combined with chemotherapy for the first-line treatment of metastatic non-small cell lung cancer

up to 2 years

Follow-up

Participants are monitored for safety and effectiveness after treatment

approximately 6 years

What Are the Treatments Tested in This Trial?

Interventions

• Ivonescimab
• Pembrolizumab

Trial Overview

This Phase 3 trial is testing Ivonescimab combined with chemotherapy against Pembrolizumab with chemotherapy as first-line treatment options for metastatic squamous NSCLC. The main goal is to see which treatment helps patients live longer without their cancer getting worse.

How Is the Trial Designed?

Group I: Arm A - Ivonescimab and chemotherapy Experimental Treatment 1 Intervention

Subject will receive ivonescimab and chemotherapy

Group II: Arm B - Pembrolizumab and chemotherapy Active Control 1 Intervention

Subject will receive pembrolizumab and chemotherapy

Ivonescimab is already approved in China for the following indications:

Approved in China as Ivonescimab for:

• Locally advanced or metastatic non-squamous NSCLC

Who Is Running the Clinical Trial?

Summit Therapeutics

Lead Sponsor

Trials

18

Recruited

4,500+

Published Research Related to This Trial

In a phase II trial involving 15 patients with resectable non-small cell lung cancer (NSCLC), neoadjuvant treatment with pembrolizumab showed a major pathologic response in 27% of patients, indicating promising antitumor activity before surgery.

The treatment was found to be feasible and safe, with only 33% of patients experiencing moderate adverse events, and no postoperative mortality, suggesting that pembrolizumab does not compromise surgical outcomes.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Neoadjuvant anti-programmed death-1 immunotherapy by pembrolizumab in resectable non-small cell lung cancer: First clinical experience. Eichhorn, F., Klotz, LV., Kriegsmann, M., et al.[2022]

A 68-year-old patient with stage IV lung adenocarcinoma showed an unexpected positive response to paclitaxel after failing treatment with pembrolizumab, an anti-PD-1 immunotherapy.

The patient experienced a response duration of over fourteen months with paclitaxel, suggesting that combining or sequencing chemotherapy with immunotherapy may enhance treatment effectiveness in certain cases.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

[Prolonged response with paclitaxel after immunotherapy by pembrolizumab in lung cancer]. Zapata, E., Mennecier, B., Leduc, C., et al.[2017]

Pembrolizumab, a PD-1 inhibitor, has demonstrated clinical effectiveness in treating various solid tumors, particularly in patients with PD-L1-positive non-small-cell lung cancer and unresectable/metastatic melanoma.

Early-phase trials and ongoing studies are focused on further confirming the clinical benefits of pembrolizumab in thoracic malignancies, highlighting its potential as a significant treatment option in cancer therapy.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Pembrolizumab for the treatment of thoracic malignancies: current landscape and future directions. Karim, S., Leighl, N.[2017]

Pembrolizumab, a monoclonal antibody targeting PD-1, showed significant efficacy in treating a 79-year-old patient with advanced squamous cell lung cancer, leading to a complete response after just 3 cycles of treatment.

However, the patient developed acute myelomonocytic leukemia after starting pembrolizumab, highlighting a potential safety concern that warrants further investigation into the drug's effects on blood cell production.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Acute myelomonocytic leukemia during pembrolizumab treatment for non-small cell lung cancer: A case report. Kim, HB., Park, SG., Hong, R., et al.[2020]

In the JAVELIN Lung 200 trial, avelumab showed improved 2-year overall survival (OS) rates compared to docetaxel in patients with higher PD-L1 expression, with rates of 36.4% for those with ≥50% PD-L1 and 40.2% for those with ≥80% PD-L1, indicating potential efficacy in specific subgroups.

Despite the primary analysis showing no significant overall survival benefit for avelumab compared to docetaxel, the longer follow-up data suggests that avelumab may be more effective for patients with higher PD-L1 expression, with a median duration of response of 19.1 months compared to 5.7 months for docetaxel.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Avelumab Versus Docetaxel in Patients With Platinum-Treated Advanced NSCLC: 2-Year Follow-Up From the JAVELIN Lung 200 Phase 3 Trial. Park, K., Özgüroğlu, M., Vansteenkiste, J., et al.[2021]

Pembrolizumab (KEYTRUDA) was approved by the FDA for treating unresectable or metastatic melanoma based on two clinical trials involving 1,374 patients, showing significant improvements in overall survival compared to ipilimumab, with hazard ratios indicating a reduced risk of death.

Patients receiving pembrolizumab also experienced significant improvements in progression-free survival, although some immune-mediated adverse reactions like hypothyroidism and pneumonitis were noted, highlighting the importance of monitoring for side effects.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

FDA Approval Summary: Pembrolizumab for the Treatment of Patients with Unresectable or Metastatic Melanoma. Barone, A., Hazarika, M., Theoret, MR., et al.[2022]

The phase I study of the OX40 agonistic monoclonal antibody GSK3174998, alone or with pembrolizumab, was well tolerated among 138 patients with advanced solid tumors, with treatment-related adverse events occurring in 51% of patients in Part 1 and 64% in Part 2, but no maximum-tolerated dose was reached.

Despite demonstrating target engagement and some immune response changes in the tumor microenvironment, GSK3174998 showed limited clinical activity, with a disease control rate of only 9% in Part 1 and no significant improvement when combined with pembrolizumab, indicating it may not be viable for further development in advanced cancers.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

First-in-human phase I study of the OX40 agonist GSK3174998 with or without pembrolizumab in patients with selected advanced solid tumors (ENGAGE-1). Postel-Vinay, S., Lam, VK., Ros, W., et al.[2023]

In a study of 550 patients with advanced non-small-cell lung cancer, pembrolizumab demonstrated a 41% objective response rate in treatment-naive patients and a 23% response rate in previously treated patients, indicating its efficacy as a treatment option.

The median overall survival was significantly longer for treatment-naive patients (22.3 months) compared to previously treated patients (10.5 months), with safety data showing that only 12% experienced grade 3-5 treatment-related adverse events, suggesting a tolerable safety profile.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Pembrolizumab in patients with advanced non-small-cell lung cancer (KEYNOTE-001): 3-year results from an open-label, phase 1 study. Leighl, NB., Hellmann, MD., Hui, R., et al.[2022]

The combination of vibostolimab and pembrolizumab is well tolerated by patients, indicating a favorable safety profile for this treatment regimen.

This combination therapy demonstrates antitumor activity, suggesting it may be an effective option for cancer treatment.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

An Anti-TIGIT Antibody with a PD-1 Inhibitor Shows Promise in Solid Tumors. [2022]

Citations

1.

pubmed.ncbi.nlm.nih.gov

pubmed.ncbi.nlm.nih.gov/38642937/

Phase 1a dose escalation study of ivonescimab (AK112/ ...

Ivonescimab is a first-in-class, humanized tetravalent bispecific antibody targeting PD-1 and VEGF-A simultaneously.

2.

ascopubs.org

ascopubs.org/doi/10.1200/JCO.2023.41.16_suppl.9087

Phase II results of ivonescimab (AK112/ SMT112), a novel ...

Ivonescimab, plus chemotherapy has shown promising anti-tumor activity in pts with advanced/metastatic NSCLC without AGA and can be administered safely.

3.

akesobio.com

akesobio.com/en/media/akeso-news/250426/

Akeso, Inc | Ivonescimab Receives NMPA Approval for First ...

Ivonescimab has shown superior efficacy over pembrolizumab in the HARMONi-2 Phase III trial, becoming the first therapy to achieve this globally.

4.

thelancet.com

thelancet.com/journals/eclinm/article/PIIS2589-5370(23)00283-3/fulltext

AK112, a novel PD-1/VEGF bispecific antibody, in ...

This study aimed to evaluate the efficacy and safety of AK112 combined with chemotherapy in patients with advanced non-small cell lung cancer ( ...

5.

jto.org

jto.org/article/S1556-0864(23)02312-2/fulltext

A Phase 1b Study of Ivonescimab, a Programmed Cell ...

Ivonescimab monotherapy was well tolerated and found to have a promising efficacy in patients with advanced or metastatic NSCLC. ClinicalTrials.

6.

akesobio.com

akesobio.com/en/media/akeso-news/240908/

WCLC 2024 | Akeso's Ivonescimab Head-to-Head Phase III ...

Ivonescimab as first-line treatment for PD-L1 positive NSCLC significantly extends median progression-free survival (mPFS) compared to pembrolizumab.